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Summary 
 The effects of subcutaneous injection of glucagon 
and/or oral administration of glycerol on blood metabolites 
and hormones of Holstein dairy cows induced with fatty 
liver disease was studied. Twenty multiparous cows were 
fed a dry cow ration supplemented with 6 kg of cracked 
corn during the dry period to increase the likelihood of fatty 
liver disease development. Cows with a body condition 
score of ≥ 3.5 points (1-5 scale) were assigned randomly to 
one of four treatment groups--saline, glucagon, glucagon 
plus glycerol, and glycerol. Following treatment, serial 
blood samples were collected to determine the effect of 
glucagon and/or glycerol on blood composition. Glucagon 
injection alone increased postpartal plasma glucose, insulin, 
glucagon, and plasma urea nitrogen and decreased plasma 
nonesterified fatty acids (NEFA). Glucagon plus glycerol 
treatment increased and sustained postpartal plasma glucose, 
insulin and decreased postpartal plasma NEFA. 
Administration of glycerol alone increased plasma 
triacylglycerol (TAG) and decreased plasma NEFA during 
the postpartal period. Early postpartal treatment of cows 
with glucagon and/or glycerol increased plasma glucose and 
decreased plasma NEFA. This response would suggest that 
these treatments with glucagon and/or glycerol would 
decrease the likelihood of fatty liver disease in dairy cows. 
 
Introduction 
 Dairy cows that are obese or over-conditioned during 
the periparturient period are susceptible to a complex of 
metabolic and infectious diseases known as fat cow 
syndrome. Fat cow syndrome is well known to commence 
as fatty liver disease before it exacerbates to other 
interrelated metabolic disorders such as ketosis and milk 
fever (decreased plasma calcium). Infectious sequelae to 
fatty liver disease include mastitis and metritis often 
associated with retained placenta. Other complications 
commonly seen with disease include left displaced 
abomasum and laminitis.  
Fatty liver disease affects cows in the late prepartal (1 wk 
before calving) and early postpartal periods (up to 2 wk 
after calving). The severity of fatty liver disease is classified 
on the basis of the percentage of accumulated TAG in the 
liver to assess the potential for deleterious effects to the 
health, productivity (kg of milk), and reproductivity of dairy 
cows. 
     Extensive studies have been undertaken to unravel the 
etiology of fatty liver disease as the underlying cause of fat 
cow syndrome. During the final weeks that immediately 
preceding parturition, feed intake progressively decreases to 
about 30% of normal on the day of parturition. This sharp 
decrease in feed intake is accompanied with an increased 
periparturient energy requirement to facilitate colostrum and 
milk production. This results in a negative energy balance. 
To accommodate this energy deficit, it is essential for the 
cow to mobilize body fat reserves. Lipolysis is upregulated 
and NEFA from adipose tissue overwhelm the liver. Part of 
NEFA is esterified to be converted into TAG that 
accumulates in the liver, causing fatty liver disease 
symptoms. It has been hypothesized that finding a 
preventative for fatty liver will likely prevent other 
interrelated metabolic disorders and infectious diseases 
during the peripartal (around calving) period. 
 Cows suffering fatty liver are treated similarly to cows 
affected with ketosis. In mild cases, they are treated with 
oral glucose precursors such as propylene glycol. In extreme 
cases, they are treated with intravenous dextrose infusion 
accompanied by intramuscular glucocorticoid injections. As 
a preventative against fatty liver disease and ketosis, 
glycerol mixed with feed has been evaluated. Glycerol 
drenches also have been assessed to alleviate ketosis. 
 Therapy of fatty liver disease is frustrating and rarely 
effective. Our research group recently demonstrated that 
continuous intravenous infusion of glucagon is efficacious 
in alleviating the fatty liver-ketosis complex in Holstein 
dairy cows. Nonetheless, intravenous injection is considered 
impractical in a dairy farm setting. Subsequently, it was 
demonstrated that subcutaneous injections of glucagon 
starting at d 8 postpartum alleviated fatty liver-ketosis 
complex symptoms from experimentally affected cows. 
More recently, we have shown that subcutaneous glucagon 
injections on d 1 prevent development of ketosis. The 
biochemical basis by which glucagon and/or glycerol exert 
their preventative action, however, is not fully understood. 
The objective of this study was to understand the 
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biochemical basis by which glucagon and/or glycerol 
prevent fatty liver disease. 
 The ultimate goal of this study is to provide the U.S. 
farmers with a slow-release subcutaneous implant of 
glucagon and/or a glycerol feeding protocol as an effective 
tool for treating fatty liver disease in dairy cows.   
 
Materials and Methods 
 Twenty multiparous Holstein dairy cows with body 
condition score of 3.5 or better were selected during the dry 
period. Cows were assigned randomly to one of four 
treatment groups that received the following treatments: 
1. Control group: Cows (n=4), starting at 6:00 h on d 1 
postpartum (after calving), received 60 mL of saline (pH 
10.25) subcutaneously at 8 h intervals for 14 days. 
2. Glucagon group: Cows (n=4), starting at 6:00 h on d 1 
postpartum, received 5 mg of glucagon dissolved in 60 mL 
of saline (pH = 10.25) subcutaneously at 8 h interval for 14 
days and once on d 15 postpartum. 
3. Glycerol group: Cows (n = 6), starting at 6:00 h on d 1 
postpartum,  received 400 mL of pure glycerol diluted with 
100 mL of water orally once daily for 14 days. 
4. Glucagon-glycerol group: Cows (n=6), starting at 6:00 h 
on d 1 postpartum, received 5 mg of glucagon dissolved in 
60 mL of saline (pH=10.25) subcutaneously at 8 h intervals 
for 14 days and once on d 15 plus 400 mL of pure glycerol 
diluted with 100 mL of water once daily for 14 days  
 Blood samples were collected on d 1, d 7, and d 13 
postpartum (after calving) using a jugular catheter. Twenty 
milliliters of blood were collected into two tubes containing 
Na2-EDTA at 15, 10, 5 min before administering each 
treatment and then at 15, 30, 45, 60, 80, 100, 120, 150, 180, 
210, 240, 300, 360, 420, and 480 min after treatment.  
Tubes were placed on ice until plasma was separated by 
centrifugation at 500 x g. Plasma was stored at – 200
for subsequent analyses. 
 
Results and discussion 
 We hypothesized that glucagon, glycerol, or glucagon 
plus glycerol could be administered to early postpartal cows 
to alleviate or prevent fatty liver disease. This clinical action 
is likely achieved by improving the energy status of the 
affected dairy cow. Our results have corroborated this 
hypothesis. Glucagon and glucagon plus glycerol treatments 
increased plasma glucose concentration (figures 1, 2, and 3). 
Glucagon plus glycerol treatment dramatically increased 
plasma glucose concentrations on d 1, d 7, and d 13 
postpartum greater than that of the control group and 
maintained it at an elevated concentration for longer time 
than did other treatments (figures 1, 2, and 3). Glucagon 
treatment decreased plasma NEFA concentrations on d 7 
and d 13 (figures 4 and 5). Glucagon plus glycerol 
decreased plasma NEFA concentrations and maintained it 
lower for longer time than other treatments on d 1 
postpartum (figure 4). Plasma NEFA concentration, 
however, was decreased by glucagon plus glycerol and 
glycerol treatments on all three sampling days. Glycerol 
treatment maintained plasma NEFA low for longer time 
than did glucagon plus glycerol treatment on d 7 and 13 
postpartum (figures 5 and 6).  
Glucagon is a potent glycogenolytic hormone that 
activates glycogen phosphorylase that causes glycogen to 
release glucose. Glucagon also increases gluconeogenesis 
by increasing liver uptake of amino acids that are used as a 
glucose precursor (data not shown). Furthermore, glucagon 
increases plasma glucose and by increasing the 
concentration of rate-limiting gluconeogenesis enzymes. 
Glycerol is an efficient glucogenic substrate (can be 
converted to glucose) because it enters the gluconeogenesis 
pathway at the triose phosphate level; glycerol conversion to 
glucose, therefore, is not affected by the rate-limiting 
enzymes phosphoenolpyruvate carboxykinase and pyruvate  
carboxylase. Glycerol can increase plasma glucose in the 
absence of propionate coming from rumen fermentation at 
time of decreased feed intake. 
 Glucagon treatment increased plasma glucagon 
concentration (figures 7, 8, and 9). Also, glucagon treatment 
increased plasma insulin on d 7 and d 13 postpartum but 
only slightly on d 1 (figures 10, 11, and 12). 
 Glucagon, glycerol, and glucagon plus glycerol 
increased plasma glucose. This response necessitates plasma 
insulin to increase. The increase in plasma insulin is an 
essential signal that indicates acute energy abundance. 
Insulin activates glucose uptake and storage by muscles and 
stimulate lipogenesis in adipose tissues. Insulin also 
stimulates ion uptake such as K+ and PO4 -3 and amino acid 
uptake and protein synthesis. Insulin also is needed to 
restrain metabolic processes that release stored body energy 
such as lipolysis, ketogenesis, and glycogenolysis. All of 
these responses suggest that glucagon and glucagon plus 
glycerol stimulate insulin release that could, in part, cause 
the metabolic responses that prevent the development of 
fatty liver by glucagon as shown in earlier research. 
 
Conclusion 
 Glucagon and glucagon plus glycerol decreased plasma 
NEFA concentration and increased plasma glucose and 
insulin concentration.  These metabolic responses may 
explain why glucagon treatment in previous research 
decreased fatty liver development. Furthermore, glucagon 
and glycerol might act additively to improve dairy cow 
postpartal energy balance. 
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Figure 1.  Effect of treatments on plasma gluccose 
concentrations on d 1 postpartum. Glucagon plus 
glycerol treatments increased plasma glucose. 
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Figure 2. Effect of treatments on plasma glucose 
concentration on d 7 postpartum. Glucagon and 
glucagon plus glycerol treatments increased plasma 
glucose. 
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Figure 3. Effect of treatments on plasma glucose 
concentration on d 13 postpartum.  Glucagon plus 
glycerol treatment increased plasma glucose 
concentration. 
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Figure 4. Effect of treatments on plasma NEFA 
concentration on d 1 postpartum. Glycerol and 
glucagon plus glycerol treatments decreased plasma 
NEFA concentration.  
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Figure 5. Effect of treatments on plasma NEFA 
concentration on d 7 postpartum. Glycerol, glucagon, 
and glucagon plus glycerol treatments decreased 
plasma NEFA concentration. 
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Figure 6. Effect of treatments on plasma NEFA 
concentration on d 13 postpartum. Glycerol, glucagon, 
and glucagon plus glycerol treatments decreased 
plasma NEFA concentration.  
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Figure 7. Effect of treatments on plasma glucagon 
concentration on d 1 postpartum. Glucagon and 
glucagon plus glycerol treatments increased plasma 
glucagon concentration. 
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Figure 8. Effect of treatments on plasma glucagon 
concentration on d 7 postpartum. Glucagon and 
glucagon plus glycerol treatments increased plasma 
glucagon concentration. 
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Figure 9. Effect of treatments on plasma glucagon 
concentration on d 13 postpartum. Glucagon and 
glucagon plus glycerol treatments increased plasma 
glucagon concentration. 
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Figure 10. Effect of treatments on plasma insulin 
concentration on d 1 postpartum. Glucagon plus 
glycerol treatment increased plasma insulin 
concentration. 
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Figure 11. Effect of treatments on plasma insulin 
concentration on d 7 postpartum. Glucagon and 
glucagon plus glycerol treatments increased plasma 
insulin concentration. 
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Figure 12. Effect of treatments on plasma insulin 
concentration on d 13 postpartum. Glucagon plus 
glycerol treatment increased plasma insulin 
concentration. 
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